Bimatoprost in the Treatment of Eyelash Hypotrichosis

Completed · Phase 3

Conditions studied: Idiopathic Eyelash Hypotrichosis

In brief

This study will evaluate the safety and efficacy of bimatoprost solution formulation A compared with bimatoprost solution 0.03% (LATISSE®) and vehicle in the treatment of eyelash hypotrichosis (inadequate eyelashes).

Key facts

Study ID

NCT01698554

Run by

Allergan

People needed

464

Starts

2012-11-01

Expected to finish

2014-03-01

Last updated by the study team

2015-02-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and female adult patients with eyelash hypotrichosis (inadequate eyelash growth).

You may not qualify if…

• Damage to eyelid area (scarring) that may prevent growth of eyelashes
• Active eye diseases (glaucoma, uveitis, eye infections, chronic blepharitis or severe dry eye)
• Eye or eyelid surgery (including laser, refractive, intraocular filtering surgery, blepharoplasty) during the 3 months prior to screening
• Current eyelash implants of any kind
• Eyelash tint or dye application within 2 months of baseline
• Eyelash extensions application within 3 months of baseline
• Use of eyelash growth products within 6 months of baseline
• Treatments that may affect hair growth (minoxidil, cancer chemotherapeutic agents, etc) within 6 months prior to baseline.

Where it is running

• Study site — Newport Beach, California, United States
• Study site — Saint Petersburg, Russia
• Study site — Stockholm, Sweden
• Study site — Norfolk, England, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.